Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Biolinerx Ltd (BLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,171
  • Shares Outstanding, K 112,121
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,960 K
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.85
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.35 +4.57%
on 05/20/19
0.45 -18.67%
on 05/07/19
unch (-1.08%)
since 04/24/19
3-Month
0.35 +4.57%
on 05/20/19
0.50 -26.45%
on 03/27/19
-0.05 (-11.81%)
since 02/22/19
52-Week
0.35 +4.57%
on 05/20/19
1.84 -80.11%
on 10/04/18
-0.53 (-59.33%)
since 05/24/18

Most Recent Stories

More News
BioCryst Down Despite Hereditary Angioedema Study Meets Goal

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

JAZZ : 136.76 (-0.48%)
BCRX : 3.32 (-6.21%)
ASRT : 3.43 (+0.88%)
BLRX : 0.37 (unch)
BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2019 and provided a corporate...

BLRX : 0.37 (unch)
BioLineRx to Report First Quarter 2019 Results on May 14, 2019

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31,...

BLRX : 0.37 (unch)
BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational...

BLRX : 0.37 (unch)
BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2018 and provided a corporate...

BLRX : 0.37 (unch)
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with...

BLRX : 0.37 (unch)
BioLineRx to Report Annual 2018 Results on March 28, 2019

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited annual financial results for the year ended December...

BLRX : 0.37 (unch)
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update...

BLRX : 0.37 (unch)
Biotech Companies Turn Their Attention to Cancer as Global Incidences Grow

In 2018, cancer was the second leading cause of death around the globe. Cancer was responsible for an estimated 9.6 million deaths in that year, or approximately one in six deaths, according to the World...

CANF : 3.00 (+1.35%)
CYCC : 0.76 (+22.26%)
ONCS : 2.49 (-3.11%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
BLRX : 0.37 (unch)
Biotech on the Brink of Breaking Out

HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now.

FBIO : 1.85 (+4.52%)
GWPH : 183.62 (-0.58%)
BLRX : 0.37 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLRX with:

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

2nd Resistance Point 0.39
1st Resistance Point 0.38
Last Price 0.37
1st Support Level 0.36
2nd Support Level 0.35

See More

52-Week High 1.84
Fibonacci 61.8% 1.27
Fibonacci 50% 1.10
Fibonacci 38.2% 0.92
Last Price 0.37
52-Week Low 0.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar